Weave (WEAV) Q2 2025: Specialty Medical Grows to 2nd Largest Vertical, Fueling 15% Expansion
Weave’s specialty medical vertical vaulted to its second-largest position, underlining the company’s vertical expansion strategy and AI-led automation push. Integration of the TrueLark acquisition is already creating new cross-sell opportunities and accelerating mid-market momentum. Management’s guidance signals confidence in sustained revenue acceleration and margin leverage into the second half, as automation and payments attach deepen across healthcare SMBs.
Summary
- Specialty Medical Expansion: Vertical now ranks second by customer count, validating Weave’s vertical integration approach.
- AI Automation and Payments Attach: TrueLark integration and payments adoption are driving new revenue vectors and operational efficiency.
- Margin Leverage Signals: Disciplined cost management and targeted hiring point to improving profitability as growth investments scale.
Performance Analysis
Weave delivered 15.6% year-over-year revenue growth in Q2 2025, surpassing the top end of guidance for the fourteenth consecutive quarter and demonstrating continued demand resilience across its core healthcare SMB base. The company’s record sales quarter was fueled by ongoing strength in the specialty medical vertical, now the second-largest by customer count, and robust momentum in payments, which continues to outpace subscription revenue growth. Gross margin reached 72.3%, up both year-over-year and sequentially, reflecting operational discipline and the scalable nature of Weave’s SaaS platform.
Free cash flow generation of $4.5 million and operating income improvement highlight the ability to balance investment in growth vectors with profitability. Notably, the TrueLark acquisition contributed just over a month of revenue and expense, but management expects the asset to be accretive in 2026 as integration deepens. Net revenue retention remained healthy at 96%, with gross revenue retention at 90%, underscoring strong customer loyalty and cross-sell opportunity.
- Payments Outperformance: Payments revenue grew faster than the core subscription business, with attach rates and usage both rising across the installed base.
- Operating Efficiency Gains: G&A expense fell to 17% of revenue, down from 19% last year, as Weave scales its platform and leverages automation.
- Investment Acceleration: Sales and R&D hiring was pulled forward to capitalize on mid-market and specialty medical momentum, with targeted investments yielding pipeline growth.
Q2 marked a record for both sales and free cash flow, while TrueLark’s early integration and the expansion of authorized EMR integrations signal further upside for the back half of the year.
Executive Commentary
"Q2 marked a record quarter for our medical vertical, driven by strong growth in medical aesthetics, primary care, and physical therapy... By unifying these AI capabilities into a single experience, Weave is positioning itself as the go-to platform for simplifying operations and increasing impact across key healthcare verticals."
Brett White, Chief Executive Officer
"Gross profit grew to $42.3 million in Q2, an increase of nearly $6 million year over year... We are making targeted investments to drive our mid-market partnerships and specialty medical growth initiatives."
Jason Christensen, Chief Financial Officer
Strategic Positioning
1. Specialty Medical Vertical Scale
Specialty medical, previously Weave’s fastest-growing vertical, now ranks second by customer count, demonstrating the effectiveness of Weave’s focused vertical entry strategy. The company’s methodical approach—beginning with core, non-integrated offerings and layering on integrations—enables initial landings at lower average selling prices, followed by upsell to higher-value bundles as integrations mature and brand equity builds. With less than 1% share of the specialty market, Weave sees significant whitespace, especially as new EMR integrations unlock deeper penetration and higher ARPU (average revenue per user).
2. TrueLark Integration and AI Automation
The TrueLark acquisition, closed in May, is already reshaping Weave’s automation and cross-sell strategy. TrueLark’s AI-powered workflow automation, previously focused on multi-location dental service organizations, is now being integrated with Weave’s go-to-market and product teams. The joint sales motion allows Weave to engage DSOs unwilling to switch core platforms by leading with TrueLark, establishing relationships and seeding future upsell. Product integration is on track for a unified inbox experience, with a broader rollout to single-location practices expected in Q4 and Q1 2026.
3. Payments Penetration and Revenue Cycle Innovation
Payments remain a major growth lever, with attach rates and usage both climbing. The company’s focus on automating revenue cycle management—accelerating collections, reducing days outstanding, and enabling text-to-pay—resonates with healthcare SMBs facing margin and staffing pressures. Management emphasized that Weave is still underpenetrated in payments, with significant upside as attach and volume capture improve.
4. Mid-Market and Multi-Location Leverage
Mid-market momentum is building, with a refreshed sales team and lower customer acquisition cost (CAC) than some legacy channels. Multi-location customers, especially in dental and specialty, offer outsized NRR (net revenue retention) as Weave expands its footprint within growing organizations. Management highlighted that multi-location customer NRR exceeds 100% when measured by location growth, though this is not yet captured in reported metrics.
5. Platform Integrations and Product Expansion
Authorized integrations with leading EMR and practice management systems, including Veradigm, Practice Fusion, Prompt, Ortho2Edge, and Idex Neo, are expanding Weave’s addressable market and deepening product stickiness. These integrations are critical for unlocking upsell, reducing churn, and enabling bundled solutions that drive ARPU expansion over time.
Key Considerations
Q2 highlighted Weave’s ability to scale its platform and penetrate new healthcare verticals, while maintaining operational discipline and investing in future growth vectors. The company is executing on multiple fronts: vertical expansion, AI automation, payments growth, and mid-market leverage.
Key Considerations:
- Vertical Penetration Model: Weave’s playbook of landing with core offerings, then upselling as integrations mature, is proving effective in specialty medical and other verticals.
- AI and Automation Differentiation: The TrueLark acquisition and unified inbox roadmap position Weave as an automation leader, driving efficiency for healthcare SMBs.
- Payments Scale Opportunity: Underpenetrated payments attach and volume represent a sizable revenue and margin lever as adoption deepens.
- Mid-Market Economics: Multi-location and mid-market sales motions are yielding lower CAC and higher NRR, pointing to scalable growth with attractive unit economics.
- Integration-Driven Upsell: Expanding EMR and practice management system integrations unlock higher-value bundles and reduce churn risk.
Risks
Integration complexity, particularly with TrueLark and new EMR partners, could delay product rollouts or limit upsell velocity if execution falters. Vertical-specific macro pressures, such as tariffs or consumer weakness, may impact certain healthcare sub-segments (e.g., optometry and dental retail), though management currently reports resilient demand. Adoption risk remains around AI-powered features, as customer readiness varies widely and some SMBs remain slow to embrace automation.
Forward Outlook
For Q3 2025, Weave guided to:
- Revenue between $60.1 million and $61.1 million
- Non-GAAP operating income of break-even to $1 million
For full-year 2025, management raised expectations for accelerated growth in the second half:
- Revenue of $236.8 million to $239.8 million
- Non-GAAP operating income of $1.2 million to $3.2 million
Management highlighted ongoing margin expansion, strong free cash flow, and confidence in multi-vertical and automation-driven growth as key drivers for the remainder of the year and into 2026.
- Integration and cross-sell of TrueLark expected to ramp in Q4 and Q1 2026
- Further operating leverage anticipated as scale and automation initiatives mature
Takeaways
Weave’s Q2 results reinforce its vertical expansion and automation-led growth thesis, with specialty medical and payments attach as outsized contributors.
- Specialty Medical Acceleration: Rapid scaling in specialty medical validates the integration-led vertical playbook and opens significant whitespace for future ARPU growth.
- Automation and AI Integration: TrueLark and unified inbox initiatives are set to deepen Weave’s competitive moat in SMB healthcare automation.
- Watch for Payments and Mid-Market Leverage: Investors should monitor payments attach, multi-location NRR, and EMR integration depth as key signals of sustainable margin and top-line expansion.
Conclusion
Weave’s Q2 showcased operational discipline, vertical momentum, and early returns from automation investments. The company’s ability to land and expand in specialty medical, deepen payments penetration, and integrate AI capabilities positions it for durable growth and margin expansion into 2026.
Industry Read-Through
Weave’s success in specialty medical and automation underscores a broader shift in healthcare SMB tech adoption, with practices increasingly seeking unified platforms that streamline patient engagement, revenue cycle, and administrative workflows. AI-powered automation and vertical-specific integrations are emerging as key differentiators, suggesting that SaaS providers able to deliver tangible efficiency gains and seamless integrations will capture outsized share. Payments attach and revenue cycle innovation are also critical levers for SaaS vendors serving healthcare and other regulated verticals facing margin pressures and staffing constraints.